

**REMARKS**

The Communication mailed April 26, 2006 has been received and reviewed. Claim 1 has been amended to remove the wording “and apoptin”. Claim 37 is to be added. All amendments were made without prejudice or disclaimer.


Basis for the new claim can be found throughout the specification, for instance, in paragraph [0011]: “(t)he invention provides novel therapeutic possibilities, for example novel combinational therapies or novel therapeutic compounds that can work alone, sequentially to, or jointly with apoptin, especially in those cases wherein p53 is (partly) non-functional.” (emphasis added).

The new claim depends from claim 1, varying only in breadth and scopes of the invention. Therefore, the new claim is not drawn to a distinct invention, but drawn to the same elected invention of claim 1.

Applicants believe that the amendment is now fully responsive. Accordingly, withdrawal of the objection is respectfully requested.

If questions should remain after consideration of the foregoing, the Examiner is kindly requested to contact applicants’ agent at the address or telephone number given herein.

Respectfully submitted,

  
Li Feng, Ph.D.  
Registration No. 57,292  
Agent for Applicants  
TRASKBRITT, PC  
P.O. Box 2550  
Salt Lake City, Utah 84110-2550  
Telephone: 801-532-1922

Date: July 19, 2006

LF/lf

Document in ProLaw